Art. -Nr.: HY-121362

Evernic Acid

Kundenbewertung

Based on 1 Customer Validation

Evernic Acid is an orally active thioredoxin reductase 1 (TrxR1) inhibitor and antiproliferative agent. Evernic Acid inhibits the proliferation and migration of human breast cancer cells. Evernic Acid blocks the NF-κB pathway by inhibiting p65 nuclear translocation and IκBα phosphorylation, thereby suppressing downstream inflammatory mediators. Evernic Acid acts as an antioxidant, anti-inflammatory agent and neuroprotective agent, protects neurons from cell death, mitochondrial dysfunction and oxidative stress damage, reduces astrocyte activation, and ameliorates dopaminergic neuron loss and neuroinflammation. Evernic Acid inhibits enoyl reductases FabI and FabZ of Plasmodium falciparum. Evernic Acid downregulates the expression of lasB and rhlA genes in Pseudomonas aeruginosa, inhibits quorum sensing and biofilm formation, and exerts antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and fungi. Evernic Acid is applicable to research related to breast cancer, Parkinson's disease, bacterial infections and fungal infections.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.71%
CAS. Nr.: 537-09-7
Formel: C₁₇H₁₆O₇
Molecular Weight:332.30

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Evernic Acid Chemical Structure

CAS. Nr.: 537-09-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Fungal Metabolite

Alle TrxR Isoform-spezifische Produkte anzeigen :

TrxR1
TrxR2

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	IC₅₀	>100 μM Compound: 1	Cytotoxicity against human Huh7.5 cells after 24 hrs by Cell-titerGlo luminescence assay Cytotoxicity against human Huh7.5 cells after 24 hrs by Cell-titerGlo luminescence assay	[PMID: 23806111]
Huh-7	IC₅₀	77.3 μM Compound: 1	Antiplasmodial activity against liver stage of Plasmodium berghei ANKA expressing GFP infected in human Huh7.5 cells assessed as reduction in PB18S gene expression after 48 hrs by qRT-PCR analysis Antiplasmodial activity against liver stage of Plasmodium berghei ANKA expressing GFP infected in human Huh7.5 cells assessed as reduction in PB18S gene expression after 48 hrs by qRT-PCR analysis	[PMID: 23806111]
KB	IC₅₀	190.4 μM Compound: 1	Cytotoxicity against human KB cells after 72 hrs by Alamar Blue assay Cytotoxicity against human KB cells after 72 hrs by Alamar Blue assay	[PMID: 23806111]

In Vitro

Evernic acid (10-150 μg/mL; 24-52 h) exerts dose-dependent antiproliferative effects on human breast cancer MCF-7 and MDA-MB-453 cell lines, with an IC₅₀ of 33.79 μg/mL at 52 h for MCF-7 cells and 121.40 μg/mL at 48 h for MDA-MB-453 cells^[1].
Evernic acid (33.79-121.40 μg/mL; 48-52 h) upregulates TrxR1 gene expression in human breast cancer MCF-7 cells and downregulates TrxR1 gene expression in MDA-MB-453 cells when treated at respective IC₅₀ concentrations for 52 h (MCF-7) and 48 h (MDA-MB-453)^[1].
Evernic acid (33.79-121.40 μg/mL; 12-24 h) inhibits migration of human breast cancer MCF-7 and MDA-MB-453 cell lines when treated at respective IC₅₀ concentrations, with significant inhibition observed at 24 h for MCF-7 cells and at 12 and 24 h for MDA-MB-453 cells^[1].
Evernic acid (33.79-121.40 μg/mL; 48-52 h) suppresses intracellular TrxR1 enzyme activity by 25% in human breast cancer MCF-7 cells and 30% in MDA-MB-453 cells when treated at respective IC₅₀ concentrations for 52 h (MCF-7) and 48 h (MDA-MB-453)^[1].
Evernic acid (1-100 μM; 6 h pre-incubation followed by 24 h co-treatment with MPP⁺) suppresses MPP⁺-induced apoptotic morphological changes in primary rat cortical neurons, and 100 μM evernic acid normalizes MPP⁺-altered Bcl-2/Bax protein expression balance^[2].
Evernic acid (100 μM; 6 h pre-incubation followed by 6 h co-treatment with MPP⁺) protects primary rat cortical neurons from MPP⁺-induced mitochondrial membrane potential loss^[2].
Evernic acid (0.1-100 μM; 6 h pre-incubation prior to MPP⁺ co-treatment) dose-dependently suppresses MPP⁺-induced ROS generation in primary rat cortical neurons^[2].
Evernic acid (100 μM; 6 h pre-incubation followed by 1 h or 24 h co-treatment with MPP⁺) inhibits the NF-κB signaling pathway in primary rat astrocytes exposed to MPP⁺, by blocking p65 nuclear translocation, reducing IκBα phosphorylation, and lowering COX-2 expression^[2].
Evernic acid (100 μM; 6 h pre-incubation prior to MPP⁺ co-treatment) suppresses MPP⁺-induced increases in pro-inflammatory cytokine (IL-1β, IL-6, TNF-α) and chemokine (CCL2) mRNA expression in primary rat astrocytes^[2].
Evernic acid (as the primary component of fraction VI) inhibits the growth of Staphylococcus aureus ATCC 29213 (MIC 0.98 μg/mL), Pseudomonas aeruginosa ATCC 27853 (MIC 31.25 μg/mL), Escherichia coli ATCC 25922 (MIC 125 μg/mL), and Candida albicans ATCC 90028 (MIC 62.5 μg/mL) in vitro^[3].
Evernic acid inhibits the expression of quorum-sensing-dependent virulence genes lasB and rhlA in Pseudomonas aeruginosa in vitro^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Human breast cancer MCF-7 and MDA-MB-453 cell lines
Concentration:

10-150 μg/mL (24 h); 10-100 μg/mL (52 h, MCF-7); 10-150 μg/mL (48 h, MDA-MB-453)
Incubation Time:

24 h; 52 h (MCF-7); 48 h (MDA-MB-453)
Result:

Suppressed the proliferation of MCF-7 and MDA-MB-453 cells in a dose-dependent manner.
Resulted in an IC₅₀ value of 33.79 μg/mL in MCF-7 cells treated for 52 h.
Resulted in an IC₅₀ value of 121.40 μg/mL in MDA-MB-453 cells treated for 48 h.

Apoptosis Analysis^[1]

Cell Line:

Human breast cancer MCF-7 and MDA-MB-453 cell lines
Concentration:

33.79 μg/mL (MCF-7, IC₅₀); 121.40 μg/mL (MDA-MB-453, IC₅₀)
Incubation Time:

52 h (MCF-7); 48 h (MDA-MB-453)
Result:

Did not change the percentage of apoptotic and necrotic cells in MCF-7 cells compared with the control group.
Caused a very low increase in the percentage of late apoptotic cells but did not affect early apoptotic and necrotic cell percentages in MDA-MB-453 cells.

Real Time qPCR^[1]

Cell Line:

Human breast cancer MCF-7 and MDA-MB-453 cell lines
Concentration:

33.79 μg/mL (MCF-7, IC₅₀); 121.40 μg/mL (MDA-MB-453, IC₅₀)
Incubation Time:

52 h (MCF-7); 48 h (MDA-MB-453)
Result:

Downregulated BAX, BCL2, and BAX/BCL2 ratio gene expression by 4.3-, 2.5-, and 2.4-fold, respectively, but did not change P53 gene expression in MCF-7 cells.
Downregulated BAX, BCL2, P53, and BAX/BCL2 ratio gene expression by 2.1-, 1.2-, 1.9-, and 1.7-fold, respectively, in MDA-MB-453 cells.\nUpregulated TrxR1 mRNA expression by 2-fold compared to the control group in MCF-7 cells.
Downregulated TrxR1 mRNA expression by 1.5-fold compared to the control group in MDA-MB-453 cells.

Western Blot Analysis^[1]

Cell Line:

Human breast cancer MCF-7 and MDA-MB-453 cell lines
Concentration:

33.79 μg/mL (MCF-7, IC₅₀); 121.40 μg/mL (MDA-MB-453, IC₅₀)
Incubation Time:

52 h (MCF-7); 48 h (MDA-MB-453)
Result:

Did not change the protein expression of BAX or P53 in MCF-7 cells.
Suppressed P53 protein expression by 5.8-fold but did not change BAX protein expression in MDA-MB-453 cells.\nDid not alter TrxR1 protein expression in either MCF-7 or MDA-MB-453 cells compared to control groups.

Cell Migration Assay^[1]

Cell Line:

Human breast cancer MCF-7 and MDA-MB-453 cell lines
Concentration:

33.79 μg/mL (MCF-7, IC₅₀); 121.40 μg/mL (MDA-MB-453, IC₅₀)
Incubation Time:

12 h, 24 h
Result:

Reduced wound closure to 30.0% at 24 h in MCF-7 cells, compared to 38.8% in the control group.
Reduced wound closure to 0.7% at 12 h and resulted in a -4.0% wound closure (negative value indicates wound enlargement) at 24 h in MDA-MB-453 cells, compared to 4.3% and 12.6% in the control group, respectively.

In Vivo

Evernic acid (5-80 mg/kg; p.o.; daily; 10 days) significantly accelerates motor function recovery, attenuates dopaminergic neuronal loss, and suppresses astroglial activation in MPTP-induced Parkinson’s disease model mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (male, 6 weeks old, 20-23 g, MPTP-induced Parkinson's disease)^[2]
Dosage:

5 mg/kg; 80 mg/kg
Administration:

p.o.; daily; 10 days
Result:

Significantly accelerated recovery of motor function after MPTP-induced impairment, as measured by rotarod testing (80 mg/kg).
Significantly attenuated MPTP-induced dopaminergic neuronal loss in both the striatum (STR) and substantia nigra (SN), as quantified by tyrosine hydroxylase (TH) densitometry in the STR and TH-positive neuron counts in the SN (80 mg/kg).
Significantly suppressed MPTP-induced astroglial activation in the STR and SN, as measured by GFAP fluorescence intensity; no effect on MPTP-induced microglial activation was observed (80 mg/kg).
Showed partial, less pronounced protective effects on dopaminergic neuronal loss and astroglial activation compared to the 80 mg/kg dose (5 mg/kg).

Chemical Information

CAS. Nr. 537-09-7
Appearance Solid
Molecular Weight 332.30
Formel C₁₇H₁₆O₇
Color White to off-white
SMILES

CC1=CC(OC(C2=C(C=C(C=C2O)OC)C)=O)=CC(O)=C1C(O)=O
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 10 mg/mL (30.09 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0093 mL

15.0466 mL

30.0933 mL

5 mM

0.6019 mL

3.0093 mL

6.0187 mL

10 mM

0.3009 mL

1.5047 mL

3.0093 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kalın ŞN, et al. Effect of evernic acid on human breast cancer MCF-7 and MDA-MB-453 cell lines via thioredoxin reductase 1: A molecular approach. J Appl Toxicol. 2023;43(8):1148-1158. [Content Brief]

[2]. Lee S, et al. Neuroprotective and Anti-Inflammatory Effects of Evernic Acid in an MPTP-Induced Parkinson's Disease Model. Int J Mol Sci. 2021;22(4):2098. Published 2021 Feb 20. [Content Brief]

[3]. Shcherbakova A, et al. Antimicrobial and antioxidant activity of Evernia prunastri extracts and their isolates. World J Microbiol Biotechnol. 2021;37(8):129. Published 2021 Jul 7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0093 mL	15.0466 mL	30.0933 mL	75.2332 mL
	5 mM	0.6019 mL	3.0093 mL	6.0187 mL	15.0466 mL
	10 mM	0.3009 mL	1.5047 mL	3.0093 mL	7.5233 mL
	15 mM	0.2006 mL	1.0031 mL	2.0062 mL	5.0155 mL
	20 mM	0.1505 mL	0.7523 mL	1.5047 mL	3.7617 mL
	25 mM	0.1204 mL	0.6019 mL	1.2037 mL	3.0093 mL
	30 mM	0.1003 mL	0.5016 mL	1.0031 mL	2.5078 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Evernic Acid

Antioxidant Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Microbial Metabolite Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Pulmonary Fibrosis Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Alle TrxR Isoform-spezifische Produkte anzeigen

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Evernic Acid Related Classifications

HY-121362 Related Classifications